HHC Gummy Sold as THC: A Dissociative ER Case With Serum Proof

In this individual case, a 32-year-old man developed a dissociative-like neurologic syndrome plus gastrointestinal symptoms after ingesting a single gummy sold as a THC product. Serum testing analytically confirmed exposure to two HHC isomers (9R-HHC and 9 S-HHC), with no other pharmaceutical or psychoactive substances detected. Symptoms resolved within 8 hours with supportive care.

This is a case report, meaning it documents one person’s clinical course in detail rather than comparing groups. Clinicians recorded symptoms and vital signs after a 32-year-old man presented soon after eating a gummy marketed as THC. Standard lab investigations (haematology and biochemistry) were checked and were reported as normal. Serum testing was used to identify HHC isomers (9R-HHC and 9 S-HHC) and to look for other pharmaceutical or psychoactive substances. The main weakness is that one case cannot show how common this reaction is, what the typical severity looks like, or whether HHC alone explains every symptom in broader populations.

HHC entered global markets around 2021 and has been detected in unregulated cannabis products, but clinical descriptions with laboratory confirmation have been limited. This 2026 medical toxicology case report focuses on what acute HHC intoxication can look like in a real hospital presentation when exposure is analytically verified. It also reflects a practical measurement problem in emergent cannabinoids: product labeling can be unreliable, and routine toxicology panels may miss newer compounds unless targeted testing is performed.

A headline might read like “HHC causes dissociative neurotoxicity,” but this paper only documents one analytically confirmed exposure and a time-linked clinical syndrome in that individual. The standout detail is the serum confirmation of both 9R-HHC and 9 S-HHC with no other detected psychoactive substances, which narrows (but does not eliminate) alternative explanations such as undisclosed co-exposures or contaminants not covered by the testing method. The case also spotlights a labeling gap: the product was sold as THC, yet testing identified HHC isomers, so the clinical question becomes about what was actually consumed rather than what was marketed. The authors place this single presentation alongside prior case descriptions that have included seizures, hallucinations, mydriasis, dyskinesia, and acute psychosis, but this report does not quantify how often those outcomes occur or under what conditions.

Only one patient was described, so the report cannot establish frequency, typical dose-response, or a predictable clinical course. The amount of HHC in the gummy was not quantified in the abstract, which makes it hard to connect symptoms to an exposure level. This describes 1 patient(s). Individual cases cannot establish patterns or causation.